Myeloma Paper of the Day, June 20th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Long-term follow-up of Phase III CASSIOPEIA trial confirms Dara maintenance is superior to observation (HR 0.49; p<0.0001), and now shows that D-VTd and Dara maintenance is better than D-VTd without maintenance (HR 0.76; p=0.048).”
Source: Robert Orlowski/X
Authors: Philippe Moreau et al.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023